Medical comms - Press Releases

Date	Title	Company
03-Aug-2020	Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million	Tiziana Life Sciences plc
03-Aug-2020	Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics	Oxford Biomedica
03-Aug-2020	UCL Technology Fund announces first close of £100m Fund 2	UCL Technology Fund
03-Aug-2020	Amryt Pharma to Host Key Opinion Leader Call on Epidermolysis Bullosa Disease Landscape	Amryt Pharma
03-Aug-2020	Enterome scientists contribute to extensive new genomic and proteomic catalog to enhance analysis of the gut microbiome and understanding of its role in human health	ENTEROME SA,
03-Aug-2020	Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis	Novartis
03-Aug-2020	ASLAN PHARMACEUTICALS APPOINTS KENNETH KOBAYASHI, MD, AS CHIEF MEDICAL OFFICER	ASLAN Pharmaceuticals
03-Aug-2020	Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)	Eli Lilly
03-Aug-2020	Ophthalmic Drug Delivery Development - Trials and Tribulations workshop	SMi Group Ltd
03-Aug-2020	New speaker session with Kiniksa Pharmaceuticals at Pre-filled Syringes East Coast 2020	SMi Group Ltd
31-Jul-2020	Horizon Discovery Group plc Half Year Trading Update	Horizon Discovery Group plc
31-Jul-2020	Alliance for Regenerative Medicine Calls for Multi-Stakeholder Pan-European Initiative to Fast-Track Real World Evidence in Support of Patient Access to Advanced Therapies	The Alliance for Regenerative Medicine (ARM)
31-Jul-2020	Novadip Biosciences to Present at the LifeSci Partners Summer Symposium	Novadip Biosciences
31-Jul-2020	AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE	Amryt
31-Jul-2020	Enterome initiates first clinical trial with EO2401 – an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate targeting aggressive brain cancer	Enterome
31-Jul-2020	Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay	Helsinn Group
31-Jul-2020	Tagrisso granted Breakthrough Therapy Designation in the US for the adjuvant treatment of patients with Stage IB-IIIA EGFR-mutated lung cancer	AstraZeneca
31-Jul-2020	RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19	RedHill Biopharma
31-Jul-2020	Invitation to the Extraordinary Shareholders’ Meeting	Biocartis Group NV
31-Jul-2020	Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD	Oxford Biomedica